Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022 / Fabiani, M., Mateo-Urdiales, A., Sacco, C., Fotakis, E.A., Rota, M.C., Petrone, D., Bressi, M., Del Manso, M., Siddu, A., Fedele, G., Stefanelli, P., Bella, A., Riccardo, F., Palamara, A.T., Rezza, G., Brusaferro, S., Pezzotti, P., Boros, S., Ceccarelli, E., D'Ancona, F.P., et al.. - In: EUROSURVEILLANCE. - ISSN 1025-496X. - 28:8(2023). [10.2807/1560-7917.ES.2023.28.8.2300105]
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
Sacco C.;Rezza G.;
2023-01-01
Abstract
Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.| File | Dimensione | Formato | |
|---|---|---|---|
|
eurosurv-28-8-2.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
226.82 kB
Formato
Adobe PDF
|
226.82 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
